Immunic (NASDAQ:IMUX) Trading Down 2.1% – Here’s Why

Immunic, Inc. (NASDAQ:IMUX) shares traded down 2.1% on Wednesday . The stock traded as low as $0.60 and last traded at $0.6094. 1,023,047 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 1,474,176 shares. The stock had previously closed at $0.6222.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IMUX shares. Chardan Capital upgraded shares of Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. HC Wainwright cut their target price on Immunic from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a report on Thursday, October 16th. D. Boral Capital restated a “buy” rating and set a $8.00 price objective on shares of Immunic in a report on Wednesday, January 7th. Finally, Roth Mkm assumed coverage on Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $7.40.

Immunic Price Performance

The company has a market capitalization of $73.30 million, a PE ratio of -0.73 and a beta of 1.54. The company’s fifty day moving average is $0.64 and its 200-day moving average is $0.78.

Immunic (NASDAQ:IMUX) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Equities research analysts forecast that Immunic, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Immunic

A number of large investors have recently made changes to their positions in IMUX. Jane Street Group LLC boosted its position in Immunic by 279.3% in the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares during the last quarter. Aberdeen Group plc lifted its stake in Immunic by 678.1% during the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after acquiring an additional 7,184,457 shares during the period. HB Wealth Management LLC purchased a new stake in shares of Immunic in the 3rd quarter valued at $81,000. Vanguard Group Inc. lifted its position in Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of Immunic in the 3rd quarter valued at about $170,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.